

Spatiotemporal profiling of Chemicals of Emerging Concern in a megacity: A case study of Lagos, Nigeria

Idera Fabunmi^{a,b,c}, Kathryn Proctor^b, Temilola Oluseyi^{a*}, Aderonke Oyeyiola^a, Kehinde Olayinka^a, Barbara Kasprzyk-Hordern^b

^aDepartment of Chemistry, University of Lagos, Lagos, Nigeria

^bDepartment of Chemistry, University of Bath, Bath BA2 7AY, UK

^cNigerian Institute for Oceanography and Marine Research, Lagos, Nigeria

*Corresponding author: toluseyi@unilag.edu.ng

The supplementary material contains eleven tables:

Table S1. Physiochemical properties of target analytes

Figure S1. Sample collection points for wastewater and surface water

Table S2. Instrument details including chromatographic retention time and mass spectrometry parameters used in the determination of target analytes

Table S3. Instrument performance data of target analytes

Table S4. Absolute and corrected recoveries in matrices sampled

Table S5. Mean concentrations (ng L⁻¹) of target compounds in influent and effluent samples

Table S6. Concentrations (ng L⁻¹) of target compounds in influent and effluent samples at WWTP1

Table S7. Concentrations (ng L⁻¹) of target compounds in influent and effluent samples at WWTP2

Table S8. Concentrations (ng L⁻¹) of target compounds in influent and effluent samples at WWTP3

Table S9. Concentrations (ng L⁻¹) of target compounds in influent and effluent samples at WWTP4

Table S10. Concentrations (ng L⁻¹) of target compounds in influent samples at SDP1

Table S11. Concentrations (ng L⁻¹) of target compounds in influent samples at SDP2

Table S12. Percentage intra and inter-site variance of target compounds in influent samples

Table S13. Maximum Environmental Concentrations (MECs), Predicted No-Effect Concentrations (PNECs) and Risk Quotients (RQs) for target compounds

Table S1. Physiochemical properties of target analytes

Micropollutant class	Micropollutant	CAS No.	Molecular Formula	Molecular Weight (g mol ⁻¹)	Water Solubility (mg L ⁻¹) ^[i]	Log Kow ^[ii]	Log Koc ^[iii]	Log Dow ^[iv]	Henry's Law Constant (atm m ³ mol ⁻¹) ^[v]	Vapour Pressure (Torr) ^[vi]	pKa (Most acidic) ^[vii]	pKa (Most basic) ^[viii]
Anaesthetic and metabolite	Ketamine	6740-88-1	C ₁₃ H ₁₆ ClNO	237.73	3.87x10 ³	3.12	2.283	3.18	1.38x10 ⁻⁸	1.76x10 ⁻⁵	-	6.46±0.20
	Norketamine	35211-10-0	C ₁₅ H ₁₁ ClN ₂ O	233.70	-	-	-	2.71	1.78x10 ⁻¹⁰	1.26x10 ⁻⁵	-	6.25±0.20
Analgesics and metabolites	Morphine	57-27-2	C ₁₇ H ₁₉ NO ₃	285.35	2.64x10 ⁴	0.72	1.163	-0.37	1.33x10 ⁻¹⁶	7.06x10 ⁻¹⁰	9.48±0.40	8.25±0.40
	Dihydromorphine	509-60-4	C ₁₇ H ₂₁ NO ₃	287.36	2.38x10 ⁴	0.93	1.185	-0.26	1.51x10 ⁻¹⁶	7.65x10 ⁻¹⁰	9.56±0.40	8.44±0.40
	Normorphine	466-97-7	C ₁₆ H ₁₇ NO ₃	271.32	2.56x10 ⁵	0.50	0.599	-2.05	6.07x10 ⁻¹⁷	2.99x10 ⁻¹⁰	9.17±0.40	9.54±0.40
	Methadone	76-99-3	C ₂₁ H ₂₇ NO	309.46	48.5	4.17	3.229	3.39	4.97x10 ⁻¹⁰	2.20x10 ⁻⁷	-	9.50±0.50
	Codeine	76-57-3	C ₁₈ H ₂₁ NO ₃	299.37	1.22x10 ⁴	1.28	1.218	-0.23	7.58x10 ⁻¹⁴	2.47x10 ⁻⁹	13.40±0.20	8.23±0.40
	Dihydrocodeine	125-28-0	C ₁₈ H ₂₃ NO ₃	301.39	6.53x10 ³	1.49	1.384	-0.11	8.61x10 ⁻¹⁴	2.48x10 ⁻⁹	14.22±0.2	8.43±0.40
	Norcodeine	467-15-2	C ₁₇ H ₁₉ NO ₃	285.35	3.92x10 ⁴	1.07	0.964	-2.28	3.45x10 ⁻¹⁴	1.51x10 ⁻⁹	13.34±0.20	9.28±0.40
	Tramadol	27203-92-5	C ₁₆ H ₂₅ NO ₂	263.38	1.15x10 ³	3.01	1.959	0.72	1.54x10 ⁻¹¹	1.02x10 ⁻⁶	14.47±0.40	9.61±0.28
	N-desmethyltramadol	75377-45-6	C ₁₅ H ₂₃ NO ₂	249.35	-	-	-	-0.27	-	9.16x10 ⁻⁶	14.46±0.40	10.56±0.10
O-desmethyltramadol	185453-02-5	C ₁₅ H ₂₃ NO ₂	249.35	-	-	-	0.38	-	3.14x10 ⁻⁷	10.00±0.10	9.61±0.28	
Antibacterial/antibiotics	Clarithromycin	81103-11-9	C ₃₈ H ₆₉ NO ₁₃	747.97	0.3	3.18	1.371	2.31	1.73x10 ⁻²⁹	5.06x10 ⁻³⁰	13.08±0.70	8.16±0.70
	Azithromycin	83905-01-5	C ₃₈ H ₇₂ N ₂ O ₁₂	749.00	0.1	3.24	1.676	-2.48	5.30x10 ⁻²⁹	2.51x10 ⁻³¹	13.28±0.70	8.59±0.70
	Trimethoprim	738-70-5	C ₁₄ H ₁₈ N ₄ O ₃	290.32	2.33x10 ³	0.73	1.896	1.13	2.39x10 ⁻¹⁴	3.74x10 ⁻¹¹	-	7.04±0.10
	Sulfamethoxazole	723-46-6	C ₁₀ H ₁₁ N ₃ O ₃ S	253.28	3.94x10 ³	0.48	1.536	-0.03	9.56x10 ⁻¹³	1.87x10 ⁻⁹	5.81±0.50	1.39±0.10
Anti-cancer	Azathioprine	446-86-6	C ₉ H ₇ N ₇ O ₂ S	277.26	272.0	-0.09	2.395	1.21	2.64x10 ⁻¹⁵	5.94x10 ⁻¹¹	-	7.47±0.20
	Methotrexate	59-05-2	C ₂₀ H ₂₂ N ₈ O ₅	454.45	2.60x10 ³	-1.28	-0.387	-7.06	1.54x10 ⁻³¹	-	3.47±0.10	5.56±0.10
	Tamoxifen	10540-29-1	C ₂₆ H ₂₉ NO	317.53	0.2	6.30	4.400	5.07	4.49x10 ⁻¹⁰	1.85x10 ⁻⁹	-	8.69±0.28
Ifosfamide	3778-73-2	C ₇ H ₁₅ Cl ₂ N ₂ O ₂ P	261.09	3.78x10 ³	0.97	1.439	0.10	1.36x10 ⁻¹¹	1.15x10 ⁻⁴	-	1.44±0.20	
Anti-depressants and metabolites	Fluoxetine	54910-89-3	C ₁₇ H ₁₈ F ₃ NO	309.33	60.3	4.65	3.050	1.92	8.90x10 ⁻⁸	1.88x10 ⁻⁶	-	10.05±0.10
	Norfluoxetine	83891-03-6	C ₁₆ H ₁₆ F ₃ NO	295.30	-	-	-	1.54	-	5.21x10 ⁻⁶	-	9.05±0.13
	Sertraline	79617-96-2	C ₁₇ H ₁₇ Cl ₂ N	306.24	3.5	5.29	3.808	3.11	5.10x10 ⁻⁸	3.85x10 ⁻⁷	-	9.47±0.40
	Citalopram	59729-33-8	C ₂₀ H ₂₁ FN ₂ O	324.40	31.1	3.74	3.230	1.50	2.69x10 ⁻¹¹	1.53x10 ⁻⁷	-	9.57±0.28
	Desmethylcitalopram	62498-67-3	C ₁₉ H ₁₉ FN ₂ O	310.37	-	-	-	0.14	-	1.40x10 ⁻⁷	-	10.50±0.10
Anti-epileptic and metabolites	Venlafaxine	93413-69-5	C ₁₇ H ₂₇ N ₁ O ₂	277.41	266.7	3.28	2.318	1.32	2.87x10 ⁻¹¹	4.92x10 ⁻⁷	14.84±0.20	9.26±0.28
	Carbamazepine	298-46-4	C ₁₅ H ₁₂ N ₂ O	236.28	17.7	2.25	2.227	2.77	1.08x10 ⁻¹⁰	5.78x10 ⁻⁷	13.94±0.20	0.49±0.20
	Carbamazepine 10,11-epoxide	36507-30-9	C ₁₅ H ₁₂ N ₂ O ₂	252.27	-	-	-	1.97	-	2.69x10 ⁻⁶	13.91±0.20	0.50±0.20
10,11 dihydro 10 hydroxycarbamazepine	29331-92-8	C ₁₅ H ₁₄ N ₂ O ₂	254.28	-	-	-	1.73	-	3.33x10 ⁻⁸	13.75±0.20	0.53±0.40	
Anti-psychotic	Quetiapine	111974-69-7	C ₂₁ H ₂₅ N ₃ O ₂ S	384.52	0.6	3.17	2.111	2.67	7.45x10 ⁻¹⁸	3.22x10 ⁻¹³	14.41±0.10	6.74±0.10
Antihistamine	Cetirizine	83881-51-0	C ₂₁ H ₂₅ ClN ₂ O ₃	388.90	1.1	-0.61	0.875	0.69	4.19x10 ⁻¹⁷	1.39x10 ⁻¹²	3.46±0.10	6.71±0.10
Beta-blocker	Atenolol	29122-68-7	C ₁₄ H ₂₂ N ₂ O ₃	266.34	685.0	-0.03	0.611	-1.71	1.37x10 ⁻¹⁸	3.82x10 ⁻¹¹	13.88±0.20	9.43±0.10
	Metoprolol	51384-51-1	C ₁₅ H ₂₅ NO ₃	267.37	4.77x10 ³	1.69	1.475	-0.38	1.40x10 ⁻¹³	4.52x10 ⁻⁷	13.89±0.20	9.43±0.10
	Propranolol	525-66-6	C ₁₆ H ₂₁ NO ₂	259.35	228.0	2.60	2.451	0.45	7.98x10 ⁻¹³	2.48x10 ⁻⁸	13.84±0.20	9.50±0.30
Calcium channel blocker	Diltiazem	42399-41-7	C ₂₂ H ₂₆ N ₂ O ₄ S	414.52	12.3	2.79	2.296	1.97	8.61x10 ⁻¹⁷	4.27x10 ⁻¹⁴	-	8.94±0.28
Cough suppressant	Pholcodine	509-67-1	C ₂₃ H ₃₀ N ₂ O ₄	398.51	1.01x10 ⁴	0.59	0.731	-0.48	3.42x10 ⁻¹⁹	3.44x10 ⁻¹⁴	13.40±0.20	8.22±0.40

Table S1. (continued)

Micropollutant class	Micropollutant	CAS No.	Molecular Formula	Molecular Weight (g mol ⁻¹)	Water Solubility (mg L ⁻¹) ^[i]	Log K _{ow} ^[ii]	Log K _{oc} ^[iii]	Log Dow ^[iv]	Henry's Law Constant (atm m ³ mol ⁻¹) ^[v]	Vapour Pressure (Torr) ^[vi]	pKa (Most acidic) ^[vii]	pKa (Most basic) ^[viii]
Anti-diabetes	Metformin	657-24-9	C ₄ H ₁₁ N ₅	129.17	1.00x10 ⁶	-2.64	-0.666	-6.45	7.64x10 ⁻¹⁶	1.33	-	12.27±0.10
	Gliclazide	21187-98-4	C ₁₅ H ₂₁ N ₃ O ₃ S	323.41	138.4	2.12	2.205	0.79	7.95x10 ⁻¹³	-	6.07±0.10	3.89±0.20
Drug precursor and metabolite	Ephedrine/pseudoephedrine	299-42-3	C ₁₀ H ₁₅ NO	165.24	7.15x10 ⁴	0.68	1.095	-1.13	8.65x10 ⁻¹¹	8.65x10 ⁻³	13.96±0.20	9.38±0.10
	Norephedrine	492-39-7	C ₉ H ₁₃ NO	151.21	1.49x10 ⁵	0.22	0.951	-1.40	3.94x10 ⁻¹¹	1.10x10 ⁻³	12.07±0.45	8.47±0.10
H ₂ receptor agonists	Ranitidine	66357-35-5	C ₁₃ H ₂₂ N ₄ O ₃ S	314.41	2.47x10 ⁴	0.29	1.141	-1.56	3.42x10 ⁻¹⁵	7.66x10 ⁻⁸	-	8.35±0.28
	Cimetidine	51481-61-9	C ₁₀ H ₁₆ N ₆ S	252.34	1.05x10 ⁴	0.57	1.850	-0.30	9.55x10 ⁻¹⁶	3.13x10 ⁻⁹	14.13±0.10	7.07±0.61
Nicotine and metabolites	Nicotine	54-11-5	C ₁₀ H ₁₄ N ₂	162.24	1.00x10 ⁶	1.00	1.683	-2.34	3.00x10 ⁻⁹	3.03x10 ⁻²	-	8.00±0.50
	Caffeine	58-08-2	C ₈ H ₁₀ N ₄ O ₂	194.19	2.63x10 ³	0.16	0.980	-0.55	3.58x10 ⁻¹¹	3.72x10 ⁻⁷	-	0.52±0.70
	Cotinine	486-56-6	C ₁₀ H ₁₂ N ₂ O	176.22	9.99x10 ⁵	0.34	1.093	0.21	3.33x10 ⁻¹²	4.21x10 ⁻⁴	-	4.72±0.12
Hypertension	1,7 dimethylxantine	611-59-6	C ₇ H ₈ N ₄ O ₂	180.17	4.14x10 ³	-0.39	0.919	0.24	1.75x10 ⁻¹²	-	8.50±0.50	0.21±0.70
	Lisinopril	76547-98-3	C ₂₁ H ₃₁ N ₃ O ₅	405.50	8.6	-0.94	-0.516	-3.23	1.89x10 ⁻²²	1.14x10 ⁻¹⁸	2.18±0.10	10.50±0.10
	Temazepam	846-50-4	C ₁₆ H ₁₃ ClN ₂ O ₂	300.75	163.9	2.15	1.678	2.79	1.13x10 ⁻⁸	6.33x10 ⁻¹³	11.66±0.40	1.58±0.50
Anti-inflammatory Stimulants and metabolites	Acetaminophen	103-90-2	C ₈ H ₉ NO ₂	151.17	3.04x10 ⁴	0.27	1.321	0.90	6.42x10 ⁻¹³	1.43x10 ⁻⁶	9.86±0.13	1.72±0.50
	Heroin	561-27-3	C ₂₁ H ₂₃ NO ₅	369.42	2.15x10 ³	1.80	1.658	-0.06	6.15x10 ⁻¹³	7.38x10 ⁻¹⁰	-	7.93±0.40
	Amphetamine	300-62-9	C ₉ H ₁₃ N	135.21	2.80x10 ⁴	1.76	1.877	-1.23	1.08x10 ⁻⁶	0.31	-	9.94±0.10
	Methamphetamine	537-46-2	C ₁₀ H ₁₅ N	149.24	1.33x10 ⁴	2.22	2.027	-1.01	2.37x10 ⁻⁶	0.15	-	10.38±0.10
	MDMA	42542-10-9	C ₁₁ H ₁₅ NO ₂	193.25	7.03x10 ³	2.28	2.183	-1.38	2.75x10 ⁻⁹	3.17x10 ⁻³	-	10.32±0.10
	MDA	101-77-9	C ₁₃ H ₁₄ N ₂	198.27	1.96x10 ³	2.18	1.761	-1.61	1.58x10 ⁻¹¹	1.52x10 ⁻⁶	-	5.32±0.25
	6-acetylmorphine	2784-73-8	C ₁₉ H ₂₁ NO ₄	327.37	-	-	-	-0.22	-	1.83x10 ⁻⁹	9.41±0.40	8.03±0.40
	Cocaine	50-36-2	C ₁₇ H ₂₁ NO ₄	303.36	1.30x10 ³	2.17	2.001	0.92	4.24x10 ⁻¹¹	1.87x10 ⁻⁶	-	8.97±0.60
	Benzoylcegonine	519-09-5	C ₁₆ H ₁₉ NO ₄	289.33	1.61x10 ³	-1.32	-0.705	-0.60	1.03x10 ⁻¹³	1.32x10 ⁻⁸	3.35±0.40	10.83±0.40
	Anhydrocegonine methylester	43021-26-7	C ₁₀ H ₁₅ NO ₂	181.23	-	-	-	0.21	-	2.19x10 ⁻²	-	7.97±0.40
Cocethylene	529-38-4	C ₁₈ H ₂₃ NO ₄	317.38	-	-	-	1.35	-	6.80x10 ⁻⁷	-	9.04±0.60	
Mephedrone	1189805-46-6	C ₁₁ H ₁₅ NO	177.24	-	-	-	1.47	-	3.84x10 ⁻³	-	7.41±0.10	
UV filter	3-benzophenone	131-57-7	C ₁₄ H ₁₂ O ₃	228.25	68.6	3.52	3.440	3.06	1.50x10 ⁻⁸	5.26x10 ⁻⁶	7.56±0.35	-
Veterinary	Tylosin	1401-69-0	C ₄₆ H ₇₇ NO ₁₇	916.12	0.5	1.05	0.205	2.14	5.77x10 ⁻³⁸	0.00	13.06±0.70	7.39±0.70
X-ray contrast media	Iopromide	73334-07-3	C ₁₈ H ₂₄ I ₃ N ₃ O ₈	791.12	23.8	-2.49	-1.672	-0.44	1.00x10 ⁻²⁸	5.00x10 ⁻³⁰	10.62±0.70	-2.60±0.70

[i] As calculated by EPI Suite at 25°C¹[ii] As calculated by EPI Suite (KOWWIN v1.68 estimate)¹[iii] As calculated by EPI Suite based on Log Know¹[iv] As calculated by Marvin Beans at pH 7.5¹[v] As calculated by EPI Suite based on Bond SAR method¹[vi] As stated on Scifinder calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (© 1994-2015 ACD/Labs)¹[vii] As stated on Scifinder calculated using Advanced Chemistry Development (ACD/Labs) Software v11.02 (© 1994-2015 ACD/Labs) at 25°C¹




Figure S1. Sample collection points for wastewater and surface water

Table S2. Instrument details including chromatographic retention time and mass spectrometry parameters used in the determination of target analytes

Micropollutant class	Micropollutant	t_R (min)	Precursor ion (m/z)	Product ion 1 (m/z)	CV (V)	CE (eV)	Product ion 2 (m/z)	CV (V)	CE (eV)	Ion ratio ^a	Internal Standard
Anaesthetic and metabolite	Ketamine	10.59	238.1	125.0	31	27	220.1	31	15	2.93 ± 0.04	Ketamine-d ₄
	Norketamine	11.08	224.0	207.1	23	12	125.0	23	27	1.00 ± 0.02	Norketamine-d ₄
Analgesics and metabolites	Morphine	3.46	286.2	165.1	53	38	152.1	53	56	0.98 ± 0.04	Morphine-d ₃
	Dihydromorphine	3.30	288.2	185.0	28	42	213.0	28	32	2.82 ± 0.14	Morphine-d ₃
	Normorphine	3.41	272.1	165.0	45	43	152.1	45	49	1.16 ± 0.05	Morphine-d ₃
	Methadone	17.59	310.2	265.1	31	15	105.1	31	28	1.50 ± 0.05	Methadone-d ₉
	Codeine	6.05	300.2	215.1	49	25	152.1	49	57	1.17 ± 0.04	Codeine-d ₆
	Dihydrocodeine	5.47	302.1	199.1	53	33	128.1	53	60	1.91 ± 0.05	Codeine-d ₆
	Norcodeine	6.45	286.1	165.1	46	40	268.2	46	20	1.11 ± 0.04	Codeine-d ₆
	Tramadol	10.97	264.0	58.0	28	45	120.7	28	46	270 ± 21.4	Metoprolol-d ₇
	N-desmethyltramadol	11.88	250.1	44.0	25	12	232.1	25	8	38.6 ± 0.06	Cocaine-d ₃
	O-desmethyltramadol	8.29	250.2	58.0	30	18	232.1	30	10	181 ± 6.40	Cotinine-d ₃
	Antibacterial/antibiotics	Clarithromycin	18.87	748.5	158.1	40	31	590.4	40	20	3.71 ± 0.03
Azithromycin		13.95	749.5	116.1	60	54	83.1	0	60	0.95 ± 0.02	EDDP-d ₃
Trimethoprim		8.43	291.2	230.2	26	26	123.1	26	36	1.07 ± 0.03	Methamphetamine-d ₅
Sulfamethoxazole		9.56	254.1	92.2	36	30	156.1	36	20	1.44 ± 0.03	Benzoylcegonine-d ₈
Azathioprine		7.75	278.0	142.0	28	13	85.0	28	20	5.49 ± 0.17	Cotinine-d ₃
Anti-cancer	Methotrexate	7.89	455.1	308.1	40	20	175.1	40	35	1.93 ± 0.50	Amphetamine-d ₅
	Tamoxifen	22.39	372.2	72.0	50	25	129.0	50	28	30.6 ± 0.91	Tamoxifen ¹³ C ₂ ¹⁵ N
	Ifosfamide	12.69	261.0	92.0	40	28	154.0	40	22	1.89 ± 0.03	Metoprolol-d ₇
Anti-depressants and metabolites	Fluoxetine	18.35	310.2	44.1	34	10	148.1	34	10	14.9 ± 0.54	Fluoxetine-d ₅
	Norfluoxetine	18.42	296.1	134.1	18	6	-	-	-	-	Fluoxetine-d ₅
	Sertraline	19.22	306.0	159.0	23	27	275.0	23	10	1.26 ± 0.02	Sertraline-d ₃
	Citalopram	15.06	325.1	262.1	46	18	109.9	46	26	21.8 ± 3.45	Citalopram-d ₆
	Desmethylcitalopram	15.17	311.4	109.0	46	27	262.0	46	18	3.58 ± 0.11	Citalopram-d ₆
	Venlafaxine	14.14	278.2	58.1	27	40	260.1	27	12	1.78 ± 0.02	Metoprolol-d ₇
Anti-epileptic and metabolites	Carbamazepine	16.15	237.0	194.1	40	20	179.1	40	38	10.6 ± 0.15	Carbamazepine ¹³ C ₆
	Carbamazepine 10,11-epoxide	13.47	253.1	180.1	39	25	210.1	39	12	1.96 ± 0.04	Carbamazepine ¹³ C ₆
	10,11 dihydro 10 hydroxycarbamazepine	13.49	255.1	194.1	20	20	179.1	20	40	9.75 ± 0.29	Carbamazepine ¹³ C ₆
Anti-psychotic	Quetiapine	17.87	384.1	253.1	50	21	221.1	50	40	1.97 ± 0.04	Quetiapine-d ₈
Antihistamine	Cetirizine	18.68	389.1	201.0	32	21	166.0	32	40	2.51 ± 0.05	Temazepam-d ₅
Beta-blocker	Atenolol	4.32	267.3	145.1	38	30	190.1	38	16	1.61 ± 0.07	Atenolol-d ₇
	Metoprolol	11.17	268.3	116.1	42	20	121.1	42	22	2.36 ± 0.04	Metoprolol-d ₇
	Propranolol	15.14	260.2	183.1	42	18	116.1	42	16	1.88 ± 0.09	Propranolol-d ₇
Calcium channel blocker	Diltiazem	16.72	415.0	178.0	40	25	310.1	40	25	23.4 ± 1.30	Carbamazepine ¹³ C ₆
Cough suppressant	Pholcodine	3.70	399.2	381.2	55	25	100.1	55	37	3.00 ± 0.43	Atenolol-d ₇

Table S2. (continued)

Micropollutant class	Micropollutant	t_R (min)	Precursor ion (m/z)	Product ion 1 (m/z)	CV (V)	CE (eV)	Product ion 2 (m/z)	CV (V)	CE (eV)	Ion ratio ^a	Internal Standard
Anti-diabetes	Metformin	2.84	130.0	60.0	30	15	71.0	30	20	1.89 ± 0.02	Metformin-d ₆
	Gliclazide	17.80	324.1	127.0	41	20	110.0	41	20	0.98 ± 0.04	Quetiapine-d ₈
Drug precursor and metabolite	Ephedrine/pseudoephedrine	7.22	166.1	148.1	23	12	133.1	23	21	6.58 ± 0.12	1S,2R-(+) Ephedrine-d ₃
	Norephedrine	6.34	152.2	134.1	23	10	117.1	23	16	2.99 ± 0.06	1S,2R-(+) Ephedrine-d ₃
H ₂ receptor agonists	Ranitidine	4.62	315.9	176.0	26	17	123.9	26	24	8.44 ± 0.50	Atenolol-d ₇
	Cimetidine	5.32	252.9	159.4	22	16	211.2	22	10	9.02 ± 0.40	Acetaminophen-d ₄
Nicotine and metabolites	Nicotine	3.34	163.1	130.0	37	20	117.0	37	20	1.37 ± 0.02	Atenolol-d ₇
	Caffeine	8.29	195.1	138.0	38	15	110.0	38	23	2.56 ± 0.05	Cotinine-d ₃
	Cotinine	7.22	177.1	80.0	34	21	98.1	34	22	2.91 ± 0.05	Cotinine-d ₃
	1,7 dimethylxantine	6.78	181.0	124.1	54	21	-	-	-	-	Cotinine-d ₃
Hypertension	Lisinopril	7.14	406.2	84.0	38	27	246.1	38	22	9.42 ± 0.30	Amphetamine-d ₅
	Temazepam	18.16	301.1	255.1	37	21	283.1	37	14	2.21 ± 0.05	Temazepam-d ₅
Anti-inflammatory	Acetaminophen	5.11	151.9	110.0	26	16	92.9	26	24	5.54 ± 0.13	Acetaminophen-d ₄
Stimulants and metabolites	Heroin	10.85	370.2	165.1	51	50	268.1	51	29	1.41 ± 0.02	Heroin-d ₉
	Amphetamine	8.39	136.2	91.1	18	16	119.1	18	8	1.20 ± 0.04	Amphetamine-d ₅
	Methamphetamine	8.51	150.2	91.1	24	19	119.1	24	10	1.73 ± 0.03	Methamphetamine-d ₅
	MDMA	8.62	194.1	163.1	24	13	105.1	24	24	2.34 ± 0.03	MDMA-d ₅
	MDA	8.59	180.0	163.1	21	11	105.1	21	22	2.73 ± 0.06	MDA-d ₅
	6-acetylmorphine	7.65	328.1	165.1	52	39	211.1	52	26	1.46 ± 0.04	Cotinine-d ₃
	Cocaine	11.32	304.2	182.1	40	20	82.1	40	31	2.75 ± 0.09	Cocaine-d ₃
	Benzoylcegonine	9.68	290.2	168.1	38	19	105.1	38	30	1.95 ± 0.03	Benzoylcegonine-d ₈
	Anhydroecgonine methylester	3.45	182.1	118.0	39	23	122.1	37	20	1.23 ± 0.03	Atenolol-d ₇
	Cocaethylene	12.91	318.2	196.2	38	20	82.1	38	30	1.90 ± 0.05	Cocaethylene-d ₃
	Mephedrone	9.79	178.1	160.1	10	12	145.0	10	22	1.55 ± 0.06	Mephedrone-d ₃
UV filter	3-benzophenone	21.23	229.0	151.0	35	18	105.0	35	20	1.58 ± 0.04	Methadone-d ₉
Veterinary	Tylosin	17.25	916.5	174.2	80	45	101.0	80	56	1.88 ± 0.07	Methadone-d ₉
X-ray contrast media	Iopromide	4.89	792.0	573.0	46	25	558.9	46	32	1.45 ± 0.06	Acetaminophen-d ₄

t_R , retention time; CV, cone voltage; CE, collision energy

^aMRM ratio: Product ion 1/Product ion 2 ratio average over the entire calibration range

Table S3. Instrument performance data of target analytes

Micropollutant class	Micropollutant	Corresponding Internal standard	Linearity		IDL _{S/N} (ng mL ⁻¹)	IQL _{S/N} (ng mL ⁻¹)	Intra-day instrument performance ^a		Inter-day instrument performance ^a	
			Range (ng mL ⁻¹)	r2			Precision (%)	Accuracy (%)	Precision (%)	Accuracy (%)
Anaesthetic and metabolite	Ketamine	Ketamine D4	0.05-500	0.999	0.01	0.05	1.3	93.6	1.8	92.5
	Norketamine	Norketamine D4	0.10-500	0.999	0.03	0.1	3.2	94	1.8	94.1
Analgesics and metabolites	Morphine	Morphine D3	1.00-500	0.997	0.3	1	2.5	97.5	2.9	99.1
	Dihydromorphine	Morphine-D3	0.05-500	0.998	0.01	0.05	2.7	108.5	4.4	106
	Normorphine	Morphine-D3	1.00-500	0.997	0.3	1	2.2	99.8	1.5	101
	Methadone	Methadone D9	0.05-400	0.998	0.01	0.05	1.4	100.2	1.5	98.7
	Codeine	Codeine D6	0.50-500	0.999	0.1	0.5	4	95.1	2	93.5
	Dihydrocodeine	Codeine D6	0.10-500	0.999	0.03	0.1	2.1	94.6	1.6	94.2
	Norcodeine	Codeine D6	1.00-500	0.999	0.3	1	4.8	98.6	2.8	98.5
	Tramadol	Metoprolol D7	1.00-500	0.999	0.01	1	1.9	98.4	1.6	100.1
	N-desmethyltramadol	Cocaine-D3	0.50-500	0.999	0.01	0.5	2.2	94.4	2.5	92.5
Antibacterial/ antibiotics	O-desmethyltramadol	MDA-D5	1.00-400	0.997	0.01	1	4.9	98.5	3.3	95.3
	Clarithromycin	Methadone D9	0.06-500	1	0.01	0.06	2.4	101.8	2.6	99.8
	Azithromycin	EDDP D3	0.11-500	0.999	0.03	0.11	2.1	98.5	3.8	95
Anti-cancer	Trimethoprim	Methamphetamine D5	0.10-500	0.999	0.03	0.1	2.2	99.5	3	96.9
	Sulfamethoxazole	Benzoylcegonine D8	0.10-500	0.999	0.03	0.1	2.4	96	3.5	95.1
	Azathioprine	Cotinine D3	0.10-500	0.998	0.03	0.1	13.9	97.4	7.6	97.5
	Methotrexate	Amphetamine D5	0.92-500	0.996	0.28	0.92	4.1	112.2	8.7	108
	Tamoxifen	Tamoxifen 13C2 15N	0.03-1000	0.998	0.01	0.03	2.4	96.8	4	96
Anti-depressants and metabolites	Ifosfamide	Metoprolol D7	0.05-500	0.999	0.01	0.05	2.7	95.3	2.4	93.6
	Fluoxetine	Fluoxetine D5	0.05-1000	0.999	0.01	0.05	1.8	98.3	1.7	96.8
	Norfluoxetine	Fluoxetine D5	0.05-500	0.998	0.01	0.05	3.1	103.1	1.5	102.7
	Sertraline	Sertraline D3	0.05-500	1	0.01	0.05	1.7	95.7	1.6	95.3
	Citalopram	Citalopram D6	0.50-500	0.999	0.05	0.5	2.6	101.8	0.7	101.2
	Desmethylcitalopram	Citalopram D6	0.05-500	0.999	0.01	0.05	3	103.4	1.8	103
	Venlafaxine	Metoprolol D7	0.04-500	1	0.01	0.04	1.7	90.5	2.5	91.2
Anti-epileptic and metabolites	Carbamazepine	Carbamazepine 13C6	0.05-500	1	0.01	0.05	1.6	92.7	2	91.7
	Carbamazepine 10,11-epoxide	Carbamazepine 13C6	0.10-500	0.998	0.03	0.1	2.1	89.9	1.6	88.9
	10,11-Dihydro-10-hydroxycarbamazepine	Carbamazepine 13C6	0.50-500	0.999	0.05	0.5	5.6	93.8	2.8	92.2
Anti-psychotic	Quetiapine	Quetiapine D8	0.05-500	0.999	0.01	0.05	1.2	96.4	1.4	95.3
Antihistamine	Cetirizine	Temazepam D5	0.08-500	1	0.02	0.08	1.3	100.8	1.3	100.5
Beta-blocker	Atenolol	Atenolol D5	0.10-500	1	0.03	0.1	2.3	96.8	2.1	95.3
	Metoprolol	Metoprolol D7	0.05-500	0.999	0.01	0.05	2	96.1	1.3	96.8
	Propranolol	Propranolol D7	0.09-500	0.999	0.03	0.09	1	106.2	2	105.4
Calcium channel blocker	Diltiazem	Carbamazepine 13C6	0.10-500	0.999	0.01	0.1	2.3	93.6	2.3	92.7
Cough suppressant	Pholcodine	Atenolol D7	1.14-500	0.994	0.35	1.14	3.3	99.2	4.7	99.5

Table S3. (continued)

Micro-pollutant class	Micro-pollutant	Corresponding Internal standard	Linearity		IDL _{S/N} (ng mL ⁻¹)	IQL _{S/N} (ng mL ⁻¹)	Intra-day instrument performance ^a		Inter-day instrument performance ^a		
			Range (ng mL ⁻¹)	r2			Precision (%)	Accuracy (%)	Precision (%)	Accuracy (%)	
Drug precursor and metabolite	Gliclazide	Carbamazepine 13C6	0.05-500	0.998	0.01	0.05	2.8	95.3	2.1	93.2	
	Ephedrine/pseudoephedrine	1S,2R-(+) Ephedrine D3	0.10-500	1	0.03	0.1	3.4	97.3	4.1	94	
		Norephedrine	1S,2R-(+) Ephedrine D3	0.50-500	0.999	0.01	0.5	5.1	95.2	4.3	96.3
H ₂ receptor agonists	Ranitidine	Cotinine D3	5.17-500	0.998	1.03	5.17	9.7	97.5	2.5	100.1	
	Cimetidine	Codeine D6	0.52-500	0.998	0.1	0.52	9	99.3	4.2	104.1	
Nicotine and metabolites	Nicotine	Codeine D6	1.00-500	0.996	0.3	1	2.4	98.4	1.2	98.3	
Hypertension	Caffeine	Cotinine D3	0.50-500	0.999	0.1	0.5	2.8	100.4	1.7	99.6	
	Cotinine	Cotinine D3	0.05-500	0.999	0.01	0.05	1.5	98.8	1.5	98.4	
	1,7 dimethylxantine	Cotinine D3	1.00-500	0.999	0.3	1	9.9	94.9	6	94.3	
	Lisinopril	Amphetamine D5	0.93-400	0.995	0.3	1	7.2	95.2	2.2	97.2	
	Temazepam	Temazepam D5	0.05-500	0.999	0.01	0.05	1.6	97.9	1	97	
Anti-inflammatory	Acetaminophen	Acetaminophen D4	0.54-500	0.999	0.11	0.54	2.6	99	1.6	97.4	
Stimulants and metabolites	Heroin	Heroin D9	0.50-500	0.999	0.1	0.5	1.8	99.3	1.9	98.2	
	Amphetamine	Amphetamine D5	0.10-500	0.999	0.03	0.1	1.6	100.7	4.4	100.8	
	Methamphetamine	Methamphetamine D5	0.10-500	0.999	0.03	0.1	1.3	101.1	2.2	101	
		MDMA	MDMA D5	0.05-500	1	0.01	0.05	1.7	99.8	1.3	99.2
	MDA	MDA D5	0.10-500	0.999	0.03	0.1	0.7	100	1.1	98.4	
	6-acetylmorphine	Cotinine D3	0.10-500	0.998	0.03	0.1	5.1	100.1	6.1	95.3	
	Cocaine	Cocaine D3	0.05-500	1	0.01	0.05	1.5	99	2.2	97.2	
	Benzoylcegonine	Benzoylcegonine D8	0.05-500	0.998	0.01	0.05	0.9	103.2	2.4	103.4	
	Anhydrocegonine methylester	Acetaminophen D4	0.50-500	0.997	0.1	0.5	2.4	98.7	2.3	101.1	
	Cocaethylene	Cocaethylene D3	0.05-500	1	0.01	0.05	1.7	94.7	2.8	95.1	
	Mephedrone	Mephedrone D3	0.05-500	0.998	0.01	0.05	2.9	85.7	1.8	87.1	
	UV filter	3-benzophenone	Methadone D9	0.05-400	0.99	0.01	0.05	4.5	86.8	3.2	84.9
	Veterinary	Tylosin	Methadone D9	0.56-500	0.997	0.11	0.56	4	100.2	2.2	99.5
	X-ray contrast media	Iopromide	Atenolol D7	5.79-500	0.99	1.16	5.79	12	105.4	5	101.2

^aInstrument performance was determined at concentration 10, 100, 500 ng mL⁻¹

IDL, Instrument detection limit; IQL, Instrument quantification limit; S/N, signal to noise ratio

Table S4. Absolute and corrected recoveries in matrices sampled

Micropollutant class	Micropollutants	Influent		Effluent		Surface water		
		Absolute	Corrected	Absolute	Corrected	Absolute	Corrected	
		Recovery (%)	Recovery (%)	Recovery (%)	Recovery (%)	Recovery (%)	Recovery (%)	
Anaesthetic and metabolite	Ketamine	41.7	111.6	53.8	115.6	68.2	107.7	
Analgesics and metabolites	Norketamine	42.2	98.9	53.9	108.6	65.7	103.2	
	Morphine	34.2	93.9	47.8	109.8	57.1	112.5	
	Dihydromorphine	19.9	95.7	31.4	96.2	45.4	92.8	
	Normorphine	30.3	109.5	38.6	106.5	42.8	87.3	
	Methadone	49.6	109	47.9	111.7	46.5	119.2	
	Codeine	39	94.8	68.4	102.8	67.5	93.1	
	Dihydrocodeine	34.7	85.7	54.8	118.6	66.4	98.5	
	Norcodeine	35.5	95.7	36.4	87.5	52.5	90.6	
	Tramadol	33.3	69.5	47	88.3	60.9	104.8	
	N-desmethyltramadol	17.9	81.3	33.4	98.8	42.2	69.1	
Antibacterial/antibiotics	O-desmethyltramadol	31.8	87.3	36	93.9	58.6	108.1	
	Clarithromycin	33.2	80.9	40.1	97.2	31	77.6	
	Azithromycin	22.2	101.1	24.5	67	21.9	86.9	
	Trimethoprim	41.4	109.6	59.8	123.7	59.2	118	
	Sulfamethoxazole	42.1	102.8	64	111	78.9	108.4	
Anti-cancer	Azathioprine	72	109.5	81.5	83.8	88.9	66.4	
	Methotrexate	39.1	98.8	30.7	114.1	22.6	95.7	
	Tamoxifen	9.5	85.2	8.7	98.4	0.2	112.8	
Anti-depressants and metabolites	Ifosfamide	33.4	89.2	41.9	80.2	62.9	90.8	
	Fluoxetine	19.8	110.7	7.1	111.1	4.4	112.3	
	Norfluoxetine	23.6	94.8	7.9	91.7	3	74.4	
	Sertraline	13.4	91.5	8.3	105	3.1	108	
	Citalopram	40.3	119.9	35.5	124.1	41.1	115	
	Desmethylcitalopram	32.5	93.1	27.5	110.9	36.2	89.5	
	Venlafaxine	23.8	70.2	36.3	89.5	58.8	96.8	
Anti-epileptic and metabolites	Carbamazepine	37.4	88.3	55.5	102.5	68.2	101.7	
	Carbamazepine 10,11-epoxide	56.7	143.7	55	126.9	94.8	136.1	
	10,11-Dihydro -10-hydroxycarbamazepine	50.3	152.2	59.5	120.6	74.1	125.1	
Anti-psychotic	Quetiapine	37.8	72.6	46.8	95.1	51.6	87.2	
Antihistamine	Cetirizine	48.6	77.3	78.8	114.3	47.9	77.3	
Beta-blocker	Atenolol	42.8	88.6	54.6	109.7	76	115.1	
	Metoprolol	36.2	97.4	53.1	104.3	71.8	107.8	
	Propranolol	38.7	105	36.1	102.7	45.4	107.2	
Calcium channel blocker	Diltiazem	36.3	118.1	30.1	82.3	43.7	82.9	
Cough suppressant	Pholcodine	13.7	42	43.1	102	76.9	119.6	
Anti-diabetes	Metformin	36.7	78.7	53	96	55.2	93.3	
Drug precursor and metabolite	Gliclazide	46.4	80.1	61.8	108.4	32.9	69.5	
	Ephedrine/pseudoephedrine	23	92.8	18.7	88.6	25.4	67.8	
	Norephedrine	26.9	85.4	28.9	100.9	28.4	78.2	
H ₂ receptor agonists	Ranitidine	70.1	97.8	46.4	106.8	65	88.6	
	Cimetidine	20.6	123.7	33.4	106.2	32.7	95.3	
Nicotine and metabolites	Nicotine	98.5	77.3	55.7	83.9	45.3	54.9	
	Caffeine	82.9	96.6	89.8	131.7	137	122.8	
	Cotinine	37.4	85.2	47.3	101.5	72	105.9	
Hypertension	1,7-dimethylxanthine	89.3	79.6	26.6	110.6	47.5	75.5	
	Lisinopril	28.6	102.3	21.9	88.5	21.4	93.7	
	Temazepam	54.5	107.3	72.5	113.9	66.3	115.3	
Anti-inflammatory	Acetaminophen	77.8	77.8	44.8	116.4	44.4	140.5	
Stimulants and metabolites	Heroin	23.9	105.3	29.1	103	54.1	100.9	
	Amphetamine	24.5	91.7	27.4	107.8	22.5	98.7	
	Methamphetamine	31.9	102.1	42.5	97.1	47.7	97.6	
	MDMA	29.4	118.5	37	112.9	50	100.9	
	MDA	30.7	99.4	30.3	99.1	28.7	99.6	
	6-acetylmorphine	33.9	103.6	40	85.4	52.9	72.6	
	Cocaine	21.7	97.4	44.9	105.2	71.4	106.9	
	Benzoylcegonine	46.5	106.3	55.1	116.4	74.2	126.2	
	Anhydroecgonine methylester	33.9	91.3	50.2	109.5	53.6	79.5	
	Cocaethylene	7.6	109.9	48.1	107.4	71.3	105.9	
	Mephedrone	18.2	94.8	22.8	103.7	22.8	97.3	
	UV filter	3-benzophenone	27	58.5	51.9	89.4	33	74.4
	Veterinary	Tylosin	34.3	98.3	50.3	110	43.8	100.4
	X-ray contrast media	Iopromide	47.2	138.5	82.1	123.7	97	143

Table S13. Maximum Environmental Concentrations (MECs), Predicted No-Effect Concentrations (PNECs) and Risk Quotients (RQs) for target compounds

Micropollutant class	Micropollutants	PNEC ($\mu\text{g L}^{-1}$)	Effluent		Surface Water		
			MEC (ng L^{-1})	RQ	MEC (ng L^{-1})	RQ	
Anaesthetic and metabolite	Ketamine	-	<MQL	-	<MQL	-	
	Norketamine	-	<MQL	-	<MQL	-	
Analgesics and metabolites	Morphine	-	<MQL	-	<MQL	-	
	Dihydromorphine	-	49.2	-	33.9	-	
	Normorphine	-	27	-	110.5	-	
	Methadone	-	<MQL	-	<MQL	-	
	Codeine	1.280 ^a	1.5	0.001	27.3	0.021	
	Dihydrocodeine	-	<MQL	-	<MQL	-	
	Norcodeine	-	<MQL	-	<MQL	-	
	Tramadol	-	542.4	-	274	-	
	N-desmethyltramadol	-	722.7	-	108.7	-	
Antibacterial/antibiotics	O-desmethyltramadol	-	1978	-	1056.9	-	
	Clarithromycin	0.050 ^b	<MQL	-	<MQL	-	
	Azithromycin	-	<MQL	-	<MQL	-	
	Trimethoprim	4.800 ^a	1043.5	0.217	57.5	0.012	
	Sulfamethoxazole	0.146 ^b	1,951.60	13.367	1685.2	11.542	
Anti-cancer	Azathioprine	-	<MQL	-	<MQL	-	
	Methotrexate	-	<MQL	-	<MQL	-	
	Tamoxifen	0.200 ^c	46.2	0.231	22.9	0.115	
Anti-depressants and metabolites	Ifosfamide	-	<MQL	-	<MQL	-	
	Fluoxetine	4.650 ^d	56.2	0.012	49	0.011	
	Norfluoxetine	-	<MQL	-	<MQL	-	
	Sertraline	-	557	-	0.3	-	
	Citalopram	-	<MQL	-	<MQL	-	
	Desmethylcitalopram	-	<MQL	-	<MQL	-	
Anti-epileptic and metabolites	Venlafaxine	-	1.2	-	<MQL	-	
	Carbamazepine	0.395 ^a	493.4	1.249	29.8	0.075	
	Carbamazepine 10,11 epoxide	-	139	-	31.8	-	
Anti-psychotic	10,11 dihydro 10 hydroxycarbamazepine	-	281	-	<MQL	-	
	Quetiapine	-	<MQL	-	<MQL	-	
Antihistamine	Cetirizine	-	<MQL	-	<MQL	-	
Beta-blocker	Atenolol	0.445 ^a	1418.1	3.187	80.4	0.181	
	Metoprolol	7.300 ^a	24.4	0.003	<MQL	-	
	Propranolol	0.094 ^a	<MQL	-	<MQL	-	
Calcium channel blocker	Diltiazem	8.200 ^b	878.7	0.107	<MQL	-	
Cough suppressant	Pholcodine	-	<MQL	-	<MQL	-	
	Metformin	-	568.7	-	8.6	-	
Anti-diabetes	Gliclazide	1.335 ^d	972.5	0.728	24.6	0.018	
	Ephedrine/pseudoephedrine	-	39.3	-	9.9	-	
Drug precursor and metabolite	Norephedrine	-	576.1	-	45.4	-	
	Ranitidine	6.600 ^a	593	0.09	139.9	0.021	
	Cimetidine	271.300 ^b	51.3	0.0002	160.7	0.001	
Nicotine and metabolites	Nicotine	-	64	-	24.3	-	
	Caffeine	-	<MQL	-	<MQL	-	
	Cotinine	-	234	-	26.5	-	
	1,7 dimethylxantine	-	6,624.30	-	465.6	-	
Hypertension	Lisinopril	-	151.5	-	10.2	-	
	Temazepam	-	<MQL	-	<MQL	-	
Anti-inflammatory Stimulants and metabolites	Acetaminophen	0.253 ^a	9169.5	36.243	9.8	0.039	
	Heroin	-	<MQL	-	<MQL	-	
	Amphetamine	-	4515.5	-	26.8	-	
	Methamphetamine	-	<MQL	-	1.8	-	
	MDMA	-	<MQL	-	<MQL	-	
	MDA	-	194	-	<MQL	-	
	6-acetylmorphine	-	<MQL	-	<MQL	-	
	Cocaine	-	<MQL	-	<MQL	-	
	Benzoyllecgonine	-	1841.6	-	<MQL	-	
	Anhydroecgonine methylester	-	42	-	20	-	
	Cocaethylene	-	<MQL	-	<MQL	-	
	Mephedrone	-	15.5	-	<MQL	-	
	3-benzophenone	-	309.1	-	<MQL	-	
	UV filter	Tylosin	-	<MQL	-	<MQL	-
	Veterinary						
	X-ray contrast media	Iopromide	-	<MQL	-	<MQL	-

References

- 1 K. Proctor, B. Petrie, R. Barden, T. Arnot and B. Kasprzyk-hordern, *Anal. Bioanal. Chem.*, 2019, **411**, 7061–7086.